

Source	Item	Pub Date	Details	Reviewer	Public Health Theme
ECDC	Communicable disease threats report, 25 - 31 October 2025, week 44	31/10/2025	The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue of the CDTR covers the period 25 October – 1 November 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya virus disease, West Nile virus, dengue, Ebola Virus Disease, Rift Valley Fever, and mpox.	RP	Emerging Infectious Diseases
WHO	Competency and outcomes framework for adolescent health and well-being	30/10/2025	This document describes health workers' competencies and behaviours necessary to advance universal health coverage for the world's adolescents. The framework proposes an adolescent-specific adaptation of the 24 competencies set out in the Global Competency and Outcomes Framework for Universal Health Coverage (2022), organized into six domains. The document also provides illustrations of how these competencies should be applied to specific concerns of adolescent health care such as growth and development, mental health and sexual and reproductive health. This guidance can serve as a reference for curriculum content and assessable outcomes specific to adolescent health and development. As such, it will help to better align health worker education and performance with adolescent health needs.	RP	Public Health Systems & Tools/Policies/Reviews
WHO	Global traditional medicine strategy 2025-2034	30/10/2025	WHO recognizes the growing role of traditional medicine worldwide and the need for evidence-based integration into health systems. In 2023, the World Health Assembly requested the development of a new global strategy for 2025–2034. Through extensive consultations with Member States, experts and stakeholders, WHO crafted a vision for universal access to safe, effective and people-centred	RP	Cross-Cutting / Other Public Health Topics

			traditional, complementary and integrative medicine. The strategy sets guiding principles and four objectives: strengthen evidence, ensure safety and regulation, integrate TCIM into health systems, and optimize its cross-sectoral value. This comprehensive process culminated in the adoption of the Global Traditional Medicine Strategy 2025–2034 by the Seventy-eighth World Health Assembly.		
WHO	Risk evaluation of circulating Middle East respiratory syndrome coronavirus (MERS-CoV) clades and lineages	27/10/2025	This document reviews current evidence from the global genomic surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) to highlight gaps in existing knowledge, proposes recommendations for further studies, and focus on better understanding the genetic diversity associated with this zoonotic virus	RP	Emerging Infectious Diseases
WHO	Taking a strategic approach to urban health: a guide for decision-makers	27/10/2025	The comprehensive report reviews what urban health entails, why it matters, and how to make progress through integrated, long-term action. It outlines the case for prioritizing urban health from epidemiologic, economic, equity, and sustainability perspectives, and shows how decisions in diverse sectors—from climate adaptation to digital transformation—affect well-being in cities. The guide centers on the idea that urban health is a shared responsibility and a strategic societal goal that requires coordination across government and with communities, civil society, and the private sector.	RP	Public Health Systems & Tools/Policies/Reviews
WHO	Dengue case management for primary health care and home-based care: Booklet for health professionals and health-care workers	27/10/2025	The Dengue Case Management for Primary Health Care and Home-Based Care booklet, developed by the WHO South-East Asia Regional Office, is a comprehensive resource designed to strengthen frontline health-care response to dengue. It outlines the natural course of dengue illness, diagnostic approaches, and evidence-based management protocols for both primary health-care settings and home-based care. With a focus on early recognition,	RP	Emerging Infectious Diseases

			appropriate fluid management, and timely referrals, the booklet empowers health-care workers to deliver effective, life-saving care in resource-limited environments. It also includes practical tools such as monitoring charts and outbreak response strategies to enhance preparedness and response during dengue surges.		
WHO	Polio transition strategic framework: Global Vision to use polio investments to build strong, resilient and equitable health systems	26/10/2025	The Global Vision to use polio investments to build strong, resilient and equitable health systems is the umbrella for the Polio transition strategic framework, which updates the Strategic Action Plan on Polio Transition (2018-2023). It builds on stakeholder feedback to set the strategic direction to sustain the polio investments – the tools, knowledge and infrastructure built to eradicate polio over the past decades – and use this legacy to keep the world polio-free and build strong, resilient and equitable health systems.	RP	Emerging Infectious Diseases
UKHSA	Shingles immunisation programme [Shingrix®]: evaluation reports	31/10/2025	Evaluation of the Shingrix® herpes zoster (shingles) vaccination programme in England: academic years 2023/24, and 2024/25.	RP	Emerging Infectious Diseases
UKHSA	Introduction of a routine varicella (MMRV) vaccination programme	31/10/2025	Introduction of a routine varicella vaccination programme for children at one year and at 18 months, with a catch-up for children aged up to 6 years	RP	Emerging Infectious Diseases
UKHSA	Vaccination crucial as meningitis cases increase	31/10/2025	Infants and young adults most at risk from serious disease.	RP	Emerging Infectious Diseases
UKHSA	Annual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile	30/10/2025	Trends in MRSA, MSSA, E. coli, Klebsiella spp. and P. aeruginosa bacteraemia and C. difficile infection by financial year.	RP	Antimicrobial Resistance (AMR)

	infections, up to and including financial year 2025 to 2026				
UKHSA	Legionnaires' disease: referral of specimens for confirmation	30/10/2025	A guide explaining how to refer samples to the UK Health Security Agency (UKHSA) to confirm a preliminary diagnosis.	RP	Emerging Infectious Diseases
UKHSA	Health Protection Report volume 19 (2025)	30/10/2025	A national public health bulletin from the UK Health Security Agency (UKHSA).	RP	Public Health Systems & Tools/Policies/Reviews
UKHSA	Legionellosis in residents of England and Wales: 2024	29/10/2025	This report presents data from the National Enhanced Legionnaires' Disease Surveillance Scheme (NELSS), covering all confirmed cases of Legionellosis among residents of England and Wales with symptom onset between January 1 and December 31, 2024. The report's purpose is to analyse confirmed cases, which meet specific clinical and laboratory criteria, and compare findings against data from previous years. Data are drawn from national surveillance scheme reporting forms and population estimates are based on the ONS census. The report will provide an epidemiological summary, analyse overall trends and examine how the COVID-19 pandemic impacted the epidemiology of Legionellosis, focusing on shifts in case numbers and demographic patterns during this period. Data will be presented by region, age, sex, and exposure category (community, healthcare-associated, or travel-associated).	RP	Emerging Infectious Diseases
UKHSA	Rabies: risk assessment, post-exposure treatment, management	29/10/2025	Guidance on assessing risk following rabies exposure, post-exposure treatment, and public health management of a suspected rabies case in the UK.	RP	Emerging Infectious Diseases
UKHSA	Thousands with undiagnosed hepatitis and HIV found in A&E testing	29/10/2025	New evaluation of NHS England's emergency department opt-out testing has identified thousands of people living unknowingly with bloodborne viruses.	RP	Emerging Infectious Diseases

UKHSA	Bloodborne viruses (BBVs): opt-out testing in emergency departments (EDs)	29/10/2025	Interim public evaluation of the opt-out BBV testing in EDs programme in England.	RP	Cross-Cutting / Other Public Health Topics
UKHSA	Latest update on Clade Ib mpox	27/10/2025	UKHSA reminds eligible groups to come forward for mpox vaccination.	RP	Emerging Infectious Diseases
UKHSA	Mpox: technical assessments	27/10/2025	Technical assessments of the risk of mpox to the UK.	RP	Emerging Infectious Diseases
UKHSA	Outbreaks under monitoring: week 43 (week ending 26 October 2025)		Latest information on disease events under monitoring.	RP	Public Health Systems & Tools/Policies/Reviews
UKHSA	Human Animal Infections and Risk Surveillance group (HAIRS)	27/10/2025	The Human Animal Infections and Risk Surveillance (HAIRS) group identifies and assesses emerging infection risks to human health.	RP	Emerging Infectious Diseases
PHA NI	Cervical screening: what you should know	29/10/2025	This leaflet provides information about cervical screening and the Northern Ireland Cervical Screening Programme. It explains how screening is carried out, who is eligible for screening, what happens at a screening appointment, and how screening samples are processed. It also covers screening test results and the risks and benefits of taking part in the screening programme.	RP	Emerging Infectious Diseases
ESRI	Who chooses science? A longitudinal investigation of the role of primary and secondary school factors in shaping science enrolments in Ireland	29/10/2025	This Bulletin summarises the findings from: C. Hannan & E. Smyth (2025), Who chooses science? A longitudinal investigation of the role of primary and secondary school factors in shaping science enrolments in Ireland, Oxford Review of Education. Available at: https://doi.org/10.1080/03054985.2025.2558707	RP	Cross-Cutting / Other Public Health Topics
PHS	Protect your baby against respiratory syncytial virus (RSV)	29/10/2025	This guide provides information on the respiratory syncytial virus (RSV) vaccine which is offered during	RP	Emerging Infectious Diseases

			pregnancy to help protect babies against serious illness caused by RSV infection.		
PHS	A profile of deaths by suicide in Scotland 2011 to 2024	28/10/2025	This release by Public Health Scotland (PHS) presents data on deaths due to probable suicide registered with the National Records of Scotland (NRS) during the 14-year period 2011–2024. The main report presents analysis of selected information held in the Scottish Suicide Information Database (ScotSID). There is a particular focus on contact with healthcare services.	RP	Cross-Cutting / Other Public Health Topics
PHS	National Infectious Respiratory Diseases Health Inequalities Plan	28/10/2025	This respiratory inequalities plan sets out how Public Health Scotland will identify and report inequalities in respiratory infections such as COVID-19, influenza and RSV. It outlines actions to improve understanding of how factors such as deprivation, ethnicity, housing, and underlying health conditions influence infection risk and outcomes. This includes a literature review, data mapping to identify gaps, and the development of case studies to inform future reporting and interventions. The aim is to strengthen evidence, collaboration and reporting on respiratory health inequalities, supporting more equitable prevention and care across Scotland.	RP	Emerging Infectious Diseases
IDSA	IDSA releases COVID-19 vaccine guidelines for people who are immunocompromised	17/10/2025	The Infectious Diseases Society of America released new COVID-19 vaccination guidelines for adults and children who are immunocompromised. Experts in infectious diseases recommend that all adults and children who are immunocompromised receive an age-appropriate COVID-19 vaccine for the 2025-2026 season. Patients should talk with their health care providers about the timing and other clinical considerations specific to their individual situations.	RP	Emerging Infectious Diseases
IDSA	In Critical Condition: The Urgent Need to Support Mpox	30/10/2025	Despite 2 public health emergency declarations, limited progress has been made in the development of essential medical countermeasures for mpox,	RP	Emerging Infectious Diseases

	Therapeutic and Diagnostic Pipelines		including therapeutics and point-of-care (POC) diagnostics. We analyzed mpox diagnostics registered in a public database in December 2022 and January 2025. The number of tests increased; however, independent validation lagged behind. While the World Health Organization has granted emergency use listing to 2 POC molecular tests, there are no independently validated antigen rapid diagnostic tests (AgRDTs) essential for decentralized detection. The therapeutics pipeline has shown minimal progress since 2022. Of 17 clinical trials, 14 evaluated direct-acting antivirals; 86% focused solely on tecovirimat, a drug that shows safety but not efficacy with documented resistance concerns. Key vulnerable populations, including children, pregnant women, and people living with human immunodeficiency virus, remain absent from studies despite higher mortality rates. Our pipeline analysis revealed a fundamental mismatch between available countermeasures and actual needs, particularly in low-resource settings.		
IDSA	Gut microbiota predicts the risk of future COVID-19 hospitalization and mortality: insights from the population-based HELIUS Study	31/10/2025	Gut microbiota are disrupted in patients hospitalized for COVID-19, with a loss of anaerobic bacteria producing butyrate. Yet, these disruptions could either be a consequence of the infection itself, or increase susceptibility from the outset. Here, we investigated whether gut microbiota influence the risk of future COVID-19 hospitalization and mortality. In 5084 participants of a population-based cohort, gut microbiota composition was associated with the risk of future severe COVID-19. Specifically, increased abundances of butyrate-producing bacteria were associated with a lower risk of severe COVID-19. Together, gut microbiota alterations precede severe COVID-19 and may represent a novel target for prevention.	RP	Emerging Infectious Diseases

IDSA	Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s	30/10/2025	Overall, antepartum and postpartum clofazimine exposures were comparable to those reported in nonpregnant women with RR-TB. Exposures were lower than expected in the postpartum period, particularly compared with the third trimester of pregnancy.	RP	Emerging Infectious Diseases
Evidence Alerts	Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis	17/10/2025	In this prespecified pooled analysis, HD-IIV demonstrated superior protection compared with SD-IIV against hospitalisation for influenza or pneumonia and also reduced the incidence of the secondary endpoints of cardiorespiratory hospitalisation, laboratory-confirmed influenza hospitalisation, and all-cause hospitalisation. Given wide eligibility for influenza vaccination, implementing HD-IIV could result in substantial public health benefits.	RP	Emerging Infectious Diseases
Evidence Alerts	Effectiveness of Colchicine for the Treatment of Long COVID: A Randomized Clinical Trial	20/10/2025	In this randomized clinical trial, among adults with long COVID, colchicine did not improve functional capacity, respiratory function, or inflammatory markers. These findings underscore the need to explore alternative therapeutic approaches for long COVID.	RP	Emerging Infectious Diseases
Evidence Alerts	Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	10/10/2025	Both ensitrelvir and nirmatrelvir accelerate oropharyngeal SARS-CoV-2 viral clearance. Ensitrelvir is an effective alternative to currently available antivirals in treating COVID-19. Although COVID-19 is now generally a mild disease, it still causes substantial morbidity, particularly in vulnerable groups, and new variants or other coronaviruses could still emerge with pandemic potential. Safe effective and affordable antivirals are needed, and these are best assessed initially in	RP	Emerging Infectious Diseases

			pharmacometric platform trials assessing viral clearance.		
WOAH	World Organisation for Animal Health hosts biothreat conference to address high stakes of global health security	27/10/2025	Amid growing concern over a fragile and conflict-prone world, the World Organisation for Animal Health (WOAH) will host a landmark global gathering to advance inclusive dialogue and the formation of transformative alliances for a more secure, healthier future.	RP	Public Health Systems & Tools/Policies/Reviews
IAEA	Fusion Energy in 2025: Six Global Trends to Watch	28/10/2025	The fusion energy landscape is evolving rapidly. Once confined to experimental research, fusion is now emerging as a strategic national priority for research and development. The IAEA World Fusion Outlook 2025 publication highlights key developments in fusion energy around the world.	RP	Environment & Health
ProMED	ProMed Mail	31/10/2025	Click through to read latest posts re infectious diseases globally.	RP	Cross-Cutting / Other Public Health Topics